Which statin has no chance of causing diabetes ??
Reading File
Finding Sources
Searching PubMed
statins AND diabetes
Searching the Web
FDA statin labels increased blood glucose diabetes risk 2026
None. No statin can be said to have zero chance of raising blood glucose or contributing to new-onset type 2 diabetes.
The effect is usually small and is most likely in people who already have prediabetes, metabolic syndrome, obesity, or elevated fasting glucose. Risk also tends to rise with higher-intensity statin treatment. A 2024 individual-participant meta-analysis confirmed a modest, dose-dependent increase in diabetes diagnoses and glycemia (Lancet Diabetes & Endocrinology meta-analysis, PMID 38554713).
Practical point: Do not stop or avoid a clearly indicated statin solely because of this concern. For most people at cardiovascular risk, prevention of heart attack and stroke outweighs the small diabetes risk. The medical-textbook guidance is to continue the statin if diabetes develops and manage glucose appropriately.
If minimizing glucose effect is especially important, clinicians sometimes consider a lower-intensity regimen or pravastatin as a reasonable option, but this is not a guarantee of zero risk and must still achieve the needed LDL reduction. Check baseline and follow-up HbA1c or fasting glucose with your prescriber.
How large is the diabetes risk with different statins?
Reading File
Reading File
Finding Sources
Searching PubMed
statins AND new-onset diabetes
Searching PubMed
pitavastatin AND diabetes
Searching the Web
statin diabetes risk individual statins atorvastatin rosuvastatin simvastatin pravastatin pitavastatin systematic review
Quick answer
The best evidence supports a small, dose-dependent class effect, but there are not reliable exact diabetes-risk percentages for each individual statin. Differences between statins are partly explained by dose intensity and the type of people prescribed them.
Overall risk
- Standard-dose statin treatment: about a 10% relative increase in new diabetes diagnoses.
- High-intensity statin treatment: about a 36% relative increase in diabetes diagnoses.
- The absolute increase is usually small and occurs mainly in people already close to the diagnostic threshold for diabetes, such as those with prediabetes, obesity, metabolic syndrome, or elevated fasting glucose.
- A practical older estimate is roughly 1 additional diabetes diagnosis per 255 people treated for 4 years, although individual risk varies greatly.
The 2024 individual-participant-data meta-analysis found most excess diagnoses represented modest upward shifts in glucose or HbA1c in people already at high baseline risk (PMID 38554713).
Relative pattern by statin
| Statin | Expected diabetes-risk pattern | Important caveat |
|---|---|---|
| Pravastatin | Possibly lowest or near-neutral | Older data even suggested fewer cases, but this is not proof of zero risk. |
| Pitavastatin | Possibly lower | Some studies suggest a favorable glucose profile, but evidence is not strong enough to promise no risk. |
| Fluvastatin | Likely low to moderate | Less potent, so often used at lower LDL-lowering intensity. |
| Lovastatin | Low to moderate | Limited modern comparative evidence. |
| Simvastatin | Moderate | Risk rises with higher dose; 80 mg is generally avoided for muscle-safety reasons. |
| Atorvastatin | Moderate to higher, especially at 40-80 mg | Common high-intensity option at 40-80 mg. |
| Rosuvastatin | Moderate to higher, especially at 20-40 mg | High-intensity dosing has the clearest signal in some trials, but baseline prediabetes strongly affects the result. |
What matters more than the brand
- Your starting diabetes risk: HbA1c 5.7-6.4%, fasting glucose 100-125 mg/dL, central obesity, high triglycerides, hypertension, or family history.
- Statin intensity and dose: higher doses cause a larger average glucose shift.
- The reason for statin therapy: after a heart attack, stroke, stent, or with very high LDL, the cardiovascular benefit almost always outweighs this small risk.
If glucose risk is a major concern, a clinician can consider:
- obtaining baseline HbA1c and fasting glucose,
- rechecking HbA1c about 3 months after starting or increasing dose,
- intensive lifestyle measures,
- using the lowest statin intensity that still meets the LDL goal,
- considering pravastatin or pitavastatin when clinically suitable, without assuming either is diabetes-proof.
Do not switch or stop a statin without considering your LDL level and cardiovascular risk.
Reading Article
PMID: 38554713
Reading Article
PMID: 39587804
Reading Article
PMID: 37934231
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC3662830/
The best estimate from randomized trials is that the diabetes effect is small overall, but rises with statin intensity and with a person’s baseline diabetes risk.
| Statin approach | Estimated new-diabetes risk |
|---|---|
| Low to moderate intensity, as a group | About 10% relative increase. In a large trial meta-analysis: 1.3% per year on a statin vs 1.2% per year on placebo, roughly 1 extra diagnosis per 1,000 people per year in that trial setting. |
| High intensity, as a group | About 36% relative increase. In the trials reviewed: 4.8% per year vs 3.5% per year, though these trials measured HbA1c more actively and included people with higher baseline risk. |
| Atorvastatin / rosuvastatin | Usually among the higher-risk choices, especially at high doses. Observational comparative data found higher diabetes rates than pravastatin: atorvastatin HR 1.22, rosuvastatin HR 1.18. |
| Simvastatin | Intermediate risk. In the same comparative cohort, HR 1.10 versus pravastatin. |
| Pravastatin | Generally among the lower-risk options, but not proven risk-free. |
| Pitavastatin | Likely lower risk than atorvastatin and rosuvastatin. A 2024 systematic review found about 14% lower risk vs atorvastatin and 23% lower risk vs rosuvastatin. It is not zero-risk. |
| Fluvastatin / lovastatin | Older observational data did not show a significant excess versus pravastatin, but evidence is less extensive and they may not provide sufficient LDL lowering for everyone. |
The most reliable high-level evidence is the 2024 individual-participant randomized-trial meta-analysis: low/moderate intensity statins increased diabetes diagnoses by 10%, and high-intensity treatment by 36%. Glucose changes themselves were small, with mean HbA1c increases of about 0.06% and 0.08%, respectively (CTT Collaboration analysis, PMID 38554713).
How to interpret this for an individual
The absolute risk depends far more on your starting metabolic risk than on the specific statin:
- Risk is concentrated in people with prediabetes, elevated HbA1c/fasting glucose, obesity, metabolic syndrome, high triglycerides, or older age.
- In the randomized-trial analysis, roughly 62% of new diabetes cases occurred in participants already in the highest quarter of baseline glucose/HbA1c.
- A primary-prevention meta-analysis found the excess was apparent mainly in study groups that already had a higher baseline diabetes rate (Masson et al., 2024, PMID 37934231).
Comparing actual observed rates
One large observational study in older adults reported crude incidence per 1,000 person-years of:
- Rosuvastatin: 34.2
- Atorvastatin: 30.7
- Simvastatin: 26.2
- Pravastatin: 22.6
- Lovastatin: 21.8
- Fluvastatin: 21.5
These are not a clean head-to-head causal ranking because patients prescribed different statins and doses can differ at baseline. Still, the adjusted comparisons also favored pravastatin over atorvastatin, rosuvastatin, and simvastatin (the comparative cohort study).
Practical takeaway: if diabetes risk is a major concern but a statin is indicated, the discussion is usually about using the lowest effective intensity, considering pravastatin or pitavastatin when clinically appropriate, and monitoring fasting glucose or HbA1c. But choosing a weaker statin solely to reduce diabetes risk can be a poor trade if it leaves LDL inadequately treated.
Find recent research comparing diabetes risk by statin
Reading File
Reading File
Searching PubMed
statins AND new-onset diabetes
Searching PubMed
pitavastatin AND atorvastatin AND diabetes
Searching PubMed
rosuvastatin AND atorvastatin AND diabetes
Searching the Web
2024 2025 statin-specific new onset diabetes pitavastatin atorvastatin rosuvastatin meta-analysis
Reading Article
PMID: 39113067
Reading Article
PMID: 39374532
Reading Article
PMID: 35606846
Reading Article
PMID: 39587804
Recent comparative research supports a lower average diabetes risk with pitavastatin than with atorvastatin or rosuvastatin, but no statin is diabetes-risk-free. Evidence for ranking all other individual statins is thinner and more confounded by dose and patient selection.
Most relevant recent studies
-
[Systematic review and meta-analysis . Tier 1 . 2024] Singh et al., Expert Review of Clinical Pharmacology (PMID 39587804)
- Included 13 studies comparing pitavastatin with atorvastatin and/or rosuvastatin.
- Pitavastatin had a lower risk of new-onset diabetes than:
- Atorvastatin: RR 0.86 (95% CI 0.79-0.93), about 14% lower relative risk
- Rosuvastatin: RR 0.77 (95% CI 0.71-0.84), about 23% lower relative risk
- Caveat: it combined randomized and observational studies, so it supports a difference but does not give one universal absolute risk per person.
-
[Randomized controlled trial . Tier 3 . 2024] LODESTAR post-hoc analysis, Hong et al., Cardiovascular Diabetology (PMID 39113067)
Directly compared high-intensity rosuvastatin and atorvastatin in people with coronary artery disease, followed for 3 years:- Rosuvastatin: 11.4% developed diabetes
- Atorvastatin: 8.8%
- Difference was not statistically significant overall: HR 1.32, 95% CI 0.98-1.77.
- Among those achieving LDL-C below 70 mg/dL, diabetes was more frequent with rosuvastatin: 13.9% vs 8.0%, HR 1.79.
- Interpretation: at high intensity, the two drugs may be fairly similar overall, though rosuvastatin could have more glycemic effect in certain settings. This is a post-hoc subgroup result, so it needs cautious interpretation.
-
[Multicenter active-comparator cohort . Tier 2 . 2022] Seo et al., Cardiovascular Diabetology (PMID 35606846)
Ten real-world databases compared new users without prior diabetes:- Pitavastatin versus atorvastatin plus rosuvastatin: HR 0.72 (95% CI 0.59-0.87)
- Pitavastatin versus atorvastatin: HR 0.69
- Pitavastatin versus rosuvastatin: HR 0.74
- Absolute observed incidence was 21.7 per 1,000 person-years with pitavastatin versus 24.2 per 1,000 person-years with atorvastatin/rosuvastatin combined.
- Useful real-world evidence, but observational comparisons cannot fully remove prescribing differences between groups.
-
[Randomized controlled trial . Tier 3 . 2024] REPRIEVE diabetes analysis, Fitch et al., Annals of Internal Medicine (PMID 39374532)
- Pitavastatin 4 mg was compared with placebo in people with HIV, median follow-up 5.6 years.
- Pitavastatin still increased diabetes risk relative to placebo, particularly in participants with multiple baseline risk factors such as prediabetes, obesity, and metabolic syndrome.
- This is important because it shows that “lower risk than atorvastatin or rosuvastatin” does not mean “no risk.”
-
[Individual-participant meta-analysis . Tier 2 . 2024] Cholesterol Treatment Trialists' Collaboration, Lancet Diabetes & Endocrinology (PMID 38554713)
This study is not a clean molecule-by-molecule comparison, but it gives the strongest estimate for the statin-class and dose effect:- Low/moderate-intensity statins: 10% relative increase in new diabetes
- High-intensity statins: 36% relative increase
- Most excess cases occurred in people already near the diabetes threshold by glucose or HbA1c.
What the current evidence suggests
| Relative diabetes-risk pattern | Statins |
|---|---|
| Lower, not zero | Pitavastatin; probably pravastatin |
| Intermediate / uncertain | Simvastatin, lovastatin, fluvastatin |
| Higher on average, especially at higher doses | Atorvastatin, rosuvastatin |
The clearest recent comparison is therefore: pitavastatin < atorvastatin and rosuvastatin for new-onset diabetes risk. The evidence is less definitive for a precise ranking of pravastatin, simvastatin, fluvastatin, and lovastatin in modern head-to-head trials.
For an individual decision, the larger driver is often baseline diabetes susceptibility rather than the statin name: HbA1c 5.7-6.4%, fasting glucose elevation, abdominal obesity, high triglycerides, metabolic syndrome, and family history matter greatly. Statin intensity and LDL-lowering requirement should still guide drug choice, because preventing heart attack and stroke usually provides substantially more benefit than this small diabetes excess.
This is a shared conversation. Sign in to Orris to start your own chat.